The plan is under an existing companion diagnostic agreement, in which Myriad is pursuing U.S. Food and Drug Administration (FDA) approval for its BRACAnalysis CDx to be used as a companion diagnostic with Pfizer’s investigational PARP (poly ADP ribose polymerase) inhibitor, talazoparib.
Talazoparib and BRACAnalysis CDx currently are under FDA review, with New Drug Application and Supplementary Premarket Approval submissions based on results from the EMBRACA trial, which evaluated talazoparib versus physician’s choice chemotherapy in patients with germline (inherited) BRCA-mutated, HER2-negative locally advanced or metastatic breast cancer. Myriad anticipates a regulatory decision from the FDA by December 2018.
Under the commercialization plan, each company remains responsible for the commercialization of its respective product.
However, the companies will collaborate on certain commercial activities intended to support the use of the BRACAnalysis CDx in identifying patients for potential treatment with talazoparib following FDA approval.
Myriad Oncology president Lloyd Sanders said: “We believe this commercial collaboration is another strong indication of Myriad’s global leadership in the field of companion diagnostics for PARP inhibitors and personalized medicine.
“We are excited to be working with Pfizer and towards ensuring patients have access to this class of drugs.”
Approximately one in eight women are diagnosed with breast cancer in the US, and one-third are diagnosed with or will progress to the metastatic stage of the disease.
Source: Company Press Release.
